Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Bayer Stops Sale of Glucose Meter Business

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/09/2013 | 12:07pm CET

By Hendrik Varnholt

FRANKFURT--German pharmaceutical company Bayer AG (>> Bayer AG) will retain its blood glucose meter business, a spokeswoman said Wednesday, confirming a Bloomberg report.

Bayer had put up the unit for sale and had been in talks with French peer Sanofi SA (>> SANOFI) about a deal which could have been valued at around $1.5 billion, people familiar with the matter told Dow Jones Newswires in December.

"We have evaluated several options and decided to retain it," Bayer HealthCare chief Joerg Reinhardt said about the glucose meter business, according to Bloomberg.

Natali Schwab, Eyk Henning and Dana Cimilluca contributed to this story.

Write to Hendrik Varnholt at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bayer AG, SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
12/14 BAYER : Studies from Bayer Update Current Data on Nerve Tissue Proteins (A tripa..
12/13 BAYER : rivaroxaban submitted to U.S. FDA for approval in patients with coronary..
12/13DJPLANT IMPACT : Needs Extra GBP7 Million Funding by April, Hands up 'For Sale' Si..
12/12 Monsanto offers cash to U.S. farmers who use controversial chemical
12/08 EU regulators to warn Bayer about Monsanto bid
12/08 BAYER : Preventive Maintenance & service solution on existing Bayer/Medrad and A..
12/08 BAYER : J-- Preventive Maintenance & service solution on existing Bayer/Medrad a..
12/08 'Right steps' point to a healthier China
12/07 BAYER : Research Conducted at Bayer Has Provided New Information about Atrial Fi..
12/07 BAYER : Findings from Bayer Has Provided New Data on Liver Cancer (Exposure-resp..
More news
News from SeekingAlpha
12/15 MY JOURNEY TO FINANCIAL INDEPENDENCE : 86-Stock November Portfolio Update - Buyi..
12/15 Nektar Therapeutics down 1% premarket after Bayer bails on agreement to devel..
12/14 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 14, 2017
12/11 Buy Celgene And Regeneron On The Dips As Insiders Are Buying
12/08 BLOOMBERG : Bayer to face EU objections to Monsanto deal in coming days
Financials (€)
Sales 2017 35 679 M
EBIT 2017 7 597 M
Net income 2017 6 179 M
Debt 2017 8 778 M
Yield 2017 2,46%
P/E ratio 2017 14,03
P/E ratio 2018 18,35
EV / Sales 2017 2,71x
EV / Sales 2018 2,48x
Capitalization 88 070 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 121 €
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER6.02%103 473
JOHNSON & JOHNSON22.95%382 722
PFIZER12.25%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.3.91%212 270
MERCK AND COMPANY-4.86%153 386